All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

Learn about treatment options, treatment failure, associated adverse effects and more.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.


Specialty Pharmacy Considerations in the Treatment of Pulmonary Arterial Hypertension

Activity Downloads

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.

Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-19-476-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.

Activity Description

Pulmonary arterial hypertension (PAH) is a relatively rare disease that is often underdiagnosed until significant damage has occurred. Fortunately, understanding of PAH is further increasing and with it, new treatment modalities and recommendations have been put forth. Patients and the entire health care system depend on specialty pharmacies to develop, research, and implement effective patient- and drug-specific clinical and cost-management programs. This activity will provide specialty pharmacists education on developments within the PAH space and perspectives on the cost/benefit equation associated with therapies in the treatment of PAH.

Learning Objectives

The target audience for this activity is pharmacists and nurses interested in or practicing in Specialty Pharmacy. After completing the activity, participants should be able to:

  • Outline the pathophysiology, risk factors, and presentation of pulmonary arterial hypertension (PAH).
  • Describe role of the nitric oxide, endothelin, and prostacyclin pathways in PAH.
  • Compare and contrast current and emerging treatments for PAH by mechanism of action, efficacy, safety, and monitoring requirements.
  • Discuss the recently updated clinical practice guidelines for management of PAH.


Martha Kingman, DNP, FNP-C
Nurse Practitioner
Pulmonary Hypertension Comprehensive Care Center
University of Texas Southwestern Medical Center at Dallas

CE Accreditation

Release Date: 9-9-2019
Expiration Date: 10-11-2020


This activity is jointly provided by ProCE, Inc. and the Illinois Council of Health-System Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-476-H01-P has been assigned to this home study knowledge-based activity (initial release date 9-9-2019). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.


This CE activity is jointly provided by ProCE, Inc. and Wild Iris Medical Education, Inc. This activity provides 1.0 contact hour of nurse CE credit.

Wild Iris Medical Education, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Martha Kingman is a speaker for Actelion Pharmaceuticals Inc./J&J, Gilead Pharmaceuticals Inc., and United Therapeutics Corporation; and an Advisory Board member for Actelion Pharmaceuticals Inc./J&J, Bayer, Gilead Pharmaceuticals Inc., and United Therapeutics Corporation. Potential conflicts of interest were resolved with a peer review process provided by James Dorociak, PharmD, MSc. A portion of grant funds received by ProCE from Actelion Pharmaceuticals US, Inc. will be used to compensate the faculty for this presentation.


This CE activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc.

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.